vs
PHIBRO ANIMAL HEALTH CORP（PAHC）与RBC Bearings INC（RBC）财务数据对比。点击上方公司名可切换其他公司
RBC Bearings INC的季度营收约是PHIBRO ANIMAL HEALTH CORP的1.2倍（$461.6M vs $373.9M），RBC Bearings INC净利率更高（14.6% vs 7.3%，领先7.3%），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs 17.0%），RBC Bearings INC自由现金流更多（$99.1M vs $8.3M），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs 5.6%）
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
该文本实际介绍的并非RBC Bearings，而是美国多佛公司。多佛是一家工业产品综合制造商，1955年成立，总部位于伊利诺伊州当纳斯格罗夫。2021年其业务分为五大板块：工程产品、清洁能源与加注、成像与识别、泵与工艺解决方案、气候与可持续技术，是标普500成分股，在纽约证券交易所上市。
PAHC vs RBC — 直观对比
损益表 — Q2 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $373.9M | $461.6M |
| 净利润 | $27.5M | $67.4M |
| 毛利率 | 35.5% | 44.3% |
| 营业利润率 | 13.5% | 22.3% |
| 净利率 | 7.3% | 14.6% |
| 营收同比 | 20.9% | 17.0% |
| 净利润同比 | 762.1% | 16.4% |
| 每股收益（稀释后） | $0.67 | $2.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $373.9M | $461.6M | ||
| Q3 25 | $363.9M | $455.3M | ||
| Q2 25 | $378.7M | $436.0M | ||
| Q1 25 | $347.8M | $437.7M | ||
| Q4 24 | $309.3M | $394.4M | ||
| Q3 24 | $260.4M | $397.9M | ||
| Q2 24 | $273.2M | $406.3M | ||
| Q1 24 | $263.2M | $413.7M |
| Q4 25 | $27.5M | $67.4M | ||
| Q3 25 | $26.5M | $60.0M | ||
| Q2 25 | $17.2M | $68.5M | ||
| Q1 25 | $20.9M | $72.7M | ||
| Q4 24 | $3.2M | $57.9M | ||
| Q3 24 | $7.0M | $54.2M | ||
| Q2 24 | $752.0K | $61.4M | ||
| Q1 24 | $8.4M | — |
| Q4 25 | 35.5% | 44.3% | ||
| Q3 25 | 32.9% | 44.1% | ||
| Q2 25 | 29.0% | 44.8% | ||
| Q1 25 | 30.1% | 44.2% | ||
| Q4 24 | 32.9% | 44.3% | ||
| Q3 24 | 32.1% | 43.7% | ||
| Q2 24 | 31.9% | 45.3% | ||
| Q1 24 | 30.2% | 43.1% |
| Q4 25 | 13.5% | 22.3% | ||
| Q3 25 | 14.1% | 21.5% | ||
| Q2 25 | 8.9% | 23.2% | ||
| Q1 25 | 9.6% | 23.0% | ||
| Q4 24 | 8.3% | 21.7% | ||
| Q3 24 | 6.8% | 21.6% | ||
| Q2 24 | 6.7% | 24.0% | ||
| Q1 24 | 7.6% | 22.8% |
| Q4 25 | 7.3% | 14.6% | ||
| Q3 25 | 7.3% | 13.2% | ||
| Q2 25 | 4.5% | 15.7% | ||
| Q1 25 | 6.0% | 16.6% | ||
| Q4 24 | 1.0% | 14.7% | ||
| Q3 24 | 2.7% | 13.6% | ||
| Q2 24 | 0.3% | 15.1% | ||
| Q1 24 | 3.2% | — |
| Q4 25 | $0.67 | $2.13 | ||
| Q3 25 | $0.65 | $1.90 | ||
| Q2 25 | $0.43 | $2.17 | ||
| Q1 25 | $0.51 | $2.33 | ||
| Q4 24 | $0.08 | $1.82 | ||
| Q3 24 | $0.17 | $1.65 | ||
| Q2 24 | $0.02 | $1.90 | ||
| Q1 24 | $0.21 | $1.92 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.5M | $107.6M |
| 总债务越低越好 | $624.2M | $990.2M |
| 股东权益账面价值 | $332.4M | $3.3B |
| 总资产 | $1.4B | $5.1B |
| 负债/权益比越低杠杆越低 | 1.88× | 0.30× |
8季度趋势，按日历期对齐
| Q4 25 | $74.5M | $107.6M | ||
| Q3 25 | $85.3M | $91.2M | ||
| Q2 25 | $77.0M | $132.9M | ||
| Q1 25 | $70.4M | $36.8M | ||
| Q4 24 | $67.1M | — | ||
| Q3 24 | $89.8M | — | ||
| Q2 24 | $114.6M | $76.8M | ||
| Q1 24 | $98.7M | $63.5M |
| Q4 25 | $624.2M | $990.2M | ||
| Q3 25 | $628.0M | $1.1B | ||
| Q2 25 | $631.7M | $915.6M | ||
| Q1 25 | $635.4M | $920.1M | ||
| Q4 24 | $639.1M | — | ||
| Q3 24 | $295.2M | — | ||
| Q2 24 | $312.1M | — | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $332.4M | $3.3B | ||
| Q3 25 | $311.7M | $3.2B | ||
| Q2 25 | $285.7M | $3.1B | ||
| Q1 25 | $266.0M | $3.0B | ||
| Q4 24 | $246.8M | $2.9B | ||
| Q3 24 | $258.5M | $2.9B | ||
| Q2 24 | $256.6M | $2.8B | ||
| Q1 24 | $270.1M | $2.8B |
| Q4 25 | $1.4B | $5.1B | ||
| Q3 25 | $1.4B | $5.1B | ||
| Q2 25 | $1.4B | $4.8B | ||
| Q1 25 | $1.3B | $4.7B | ||
| Q4 24 | $1.3B | $4.7B | ||
| Q3 24 | $966.3M | $4.7B | ||
| Q2 24 | $982.2M | $4.7B | ||
| Q1 24 | $979.0M | $4.7B |
| Q4 25 | 1.88× | 0.30× | ||
| Q3 25 | 2.01× | 0.34× | ||
| Q2 25 | 2.21× | 0.29× | ||
| Q1 25 | 2.39× | 0.30× | ||
| Q4 24 | 2.59× | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | — | 0.43× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | $122.1M |
| 自由现金流经营现金流 - 资本支出 | $8.3M | $99.1M |
| 自由现金流率自由现金流/营收 | 2.2% | 21.5% |
| 资本支出强度资本支出/营收 | 3.0% | 5.0% |
| 现金转化率经营现金流/净利润 | 0.70× | 1.81× |
| 过去12个月自由现金流最近4个季度 | $47.3M | — |
8季度趋势，按日历期对齐
| Q4 25 | $19.4M | $122.1M | ||
| Q3 25 | $9.3M | $88.4M | ||
| Q2 25 | $21.3M | $120.0M | ||
| Q1 25 | $43.2M | — | ||
| Q4 24 | $3.1M | $84.0M | ||
| Q3 24 | $12.6M | — | ||
| Q2 24 | $28.4M | $97.4M | ||
| Q1 24 | $11.4M | — |
| Q4 25 | $8.3M | $99.1M | ||
| Q3 25 | $-4.5M | $71.7M | ||
| Q2 25 | $8.1M | $104.3M | ||
| Q1 25 | $35.4M | — | ||
| Q4 24 | $-4.7M | $73.6M | ||
| Q3 24 | $3.0M | — | ||
| Q2 24 | $15.4M | $88.4M | ||
| Q1 24 | $1.7M | — |
| Q4 25 | 2.2% | 21.5% | ||
| Q3 25 | -1.2% | 15.7% | ||
| Q2 25 | 2.1% | 23.9% | ||
| Q1 25 | 10.2% | — | ||
| Q4 24 | -1.5% | 18.7% | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 5.6% | 21.8% | ||
| Q1 24 | 0.6% | — |
| Q4 25 | 3.0% | 5.0% | ||
| Q3 25 | 3.8% | 3.7% | ||
| Q2 25 | 3.5% | 3.6% | ||
| Q1 25 | 2.2% | 3.2% | ||
| Q4 24 | 2.5% | 2.6% | ||
| Q3 24 | 3.7% | 4.1% | ||
| Q2 24 | 4.8% | 2.2% | ||
| Q1 24 | 3.7% | — |
| Q4 25 | 0.70× | 1.81× | ||
| Q3 25 | 0.35× | 1.47× | ||
| Q2 25 | 1.24× | 1.75× | ||
| Q1 25 | 2.07× | — | ||
| Q4 24 | 0.97× | 1.45× | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 37.80× | 1.59× | ||
| Q1 24 | 1.36× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
